TACE Combined With Anlotinib Treatment of Middle-advanced Hepatocellular Carcinoma (HCC) Patients

NCT04066543 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Carcinoma, Hepatocellular

Interventions

DEVICE: TACE
DRUG: Anlotinib Hydrochloride

Sponsor

Zhejiang Cancer Hospital